Pal-AHK vs Testagen
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Pal-AHK is the palmitoylated form of the AHK-Cu copper tripeptide, created by attaching a palmitic acid chain to enhance skin penetration and lipid bilayer affinity. The palmitoyl modification significantly improves dermal bioavailability compared to unmodified AHK, making it particularly effective in anti-aging and hair growth formulations.
- Testagen is a tetrapeptide bioregulator (Lys-Glu-Asp-Gly) developed by Professor Vladimir Khavinson, tissue-specific for the testes. It supports Leydig cell function, normalization of testosterone biosynthesis, and spermatogenic activity. Testagen is used in men's health protocols for age-related testosterone decline, male fertility support, and testicular anti-aging.
- Half-Life
- Extended (lipid depot effect in stratum corneum)
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- Topical
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 0.01–0.05% in formulation
- 10 mg per day
- Frequency
- Once or twice daily
- Daily for 10–30 days
- Key Benefits
- Enhanced skin penetration vs. unmodified AHK-Cu
- Stimulates dermal collagen and elastin production
- Promotes hair follicle anagen phase
- Antioxidant and wound healing activity
- Firming and plumping effect on aging skin
- Improved bioavailability via lipid bilayer incorporation
- Supports endogenous testosterone synthesis via Leydig cell normalization
- Promotes spermatogenesis and sperm quality
- Anti-aging effects on testicular tissue
- May attenuate age-related testosterone decline
- Mechanistically distinct from TRT — does not suppress HPG axis
- Useful adjunct to Gonadorelin and Kisspeptin-10 in male hormonal protocols
- Supports male fertility without exogenous hormone replacement
- Side Effects
- Generally well-tolerated
- Mild irritation at high concentrations in sensitive skin
- Possible comedogenicity at very high palmitate concentrations (formulation-dependent)
- Generally well tolerated
- Mild injection site reactions
- No significant endocrine disruption reported at standard doses
- Stacks With
- —
- —